secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108821
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered
-----------------------------------------------------------------

- Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).
- GAAP diluted EPS $0.61; non-GAAP adjusted diluted EPS $1.01 (up 16% YoY).
- Adjusted EBITDA $518M (32.3% margin), up from $459M (29.0%) YoY.
- FY2025 revenue guidance cut to $6.200-6.250B; Adj EBITDA margin guidance ~31.0% (lowered).
- Nexplanon sales down 9% ex-FX due to lower U.S. government funding; Biosimilars up 19% on Hadlima.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/0001104659-25-108821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer